Dr. Alka Khera
Neurology (Neurology Physician)
- Medicare participating
At a glance
- In the NPI registry since
- 2015
- Medicare patients seen, 2024
- 354
Licensed in Texas since 2019, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2015Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Neurology Physician primary
TX license S0477 (first issued 2019; active) - Student in an Organized Health Care Education/Training Program
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Medicare patients and services
- Medicare patients, 2024
- 354
- Services billed
- 686
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 170 | 140 |
| Established patient office or other outpatient visit, 40-54 minutes | 101 | 93 |
| New patient office or other outpatient visit, 60-74 minutes | 85 | 85 |
| Established patient office or other outpatient visit, 20-29 minutes | 30 | 28 |
| New patient office or other outpatient visit, 45-59 minutes | 21 | 21 |
| Administration of psychological or neuropsychological test by technician, each additional 30 minutes | 16 | 14 |
| Administration of psychological or neuropsychological test by technician, first 30 minutes | 15 | 15 |
| Evaluation of neuropsychological test, first hour | 15 | 15 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Donepezil Hcl Other prescribers in Dallas, TX | 555 |
| Memantine Hcl Other prescribers in Dallas, TX | 375 |
| Sertraline Hcl Other prescribers in Dallas, TX | 165 |
| Galantamine Er (galantamine hbr) Other prescribers in Dallas, TX | 100 |
| Rivastigmine Other prescribers in Dallas, TX | 64 |
| Mirtazapine Other prescribers in Dallas, TX | 45 |
| Trazodone Hcl Other prescribers in Dallas, TX | 30 |
| Memantine Hcl Er (memantine hcl) Other prescribers in Dallas, TX | 30 |
| Levetiracetam Other prescribers in Dallas, TX | 25 |
| Duloxetine Hcl Other prescribers in Dallas, TX | 15 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 3 companies reported 3 payments worth $229 in total to this clinician.
| Biogen, Inc. | $115 |
|---|---|
| F. Hoffmann-la Roche AG | $80.00 |
| Lilly USA, LLC | $33.37 |
| Food and Beverage | $229 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 7 industry-funded studies in 2025, from 4 companies. The companies reported $646,981 in research payments for these studies, mostly to the institutions running them.
- A Randomized, Double-blind, Placebo-controlled, Global Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, in Participants with Early Alzheimers Disease (Targe…
E.r. Squibb & Sons, L.l.c. - A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)
Eli Lilly and Company · Active, not recruiting · NCT06653153 - A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)
Eli Lilly and Company · Active, not recruiting · NCT05738486 - A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1)
Eli Lilly and Company · Completed · NCT05463731 - PoM study of Brain Shuttle Gantenerumab in early AD
Genentech, Inc. - A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of ABBV-1758 in Subjects with Alzheimer s Disease
AbbVie Inc. - A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)
Eli Lilly and Company · Active, not recruiting · NCT04437511
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.